Login to Your Account

Late-stage drug companies take more than half of China’s venture capital pie

By Shannon Ellis
Staff Writer

Wednesday, March 19, 2014

SHANGHAI – In 2013, venture capital (VC) activity in China’s life sciences sector remained strong, dipping only slightly below the year previous. Investor enthusiasm did not diminish even when China barred companies from holding initial public offerings (IPO) here, the exit of choice for VCs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription